Alpelisib Challenge Test (ACT)

Inclusion criteria

• Adults aged 18-70 years
• Able to understand wrifen and spoken English and/or Spanish
• Body mass index of 18-45 kg/m2 (or 18-42 kg/m2 for those of Asian ancestry)
• For Lean group: BMI 18.0-24.9 kg/m2 (or 18.0-22.9 kg/m2 for those of Asian ancestry)
• For Overweight group: BMI 25.0-29.9 kg/m2 (or 23.0-27.4 kg/m2 for those of Asian ancestry)
• For Obesity group: BMI 30.0-45.0 kg/m2 (or 27.5-42 kg/m2 for those of Asian ancestry)

Exclusion criteria

• Inability to provide informed consent in English or Spanish
• Unwillingness to fast (except water) for up to 18 hours
• Unwillingness not to get out of bed and to use bedpan/urinal to void for up to 15 hours
• Documented weight change of ≥ 5.0% of baseline within the previous 3 months
• Abnormal blood pressure
• Systolic blood pressure \< 90 mm Hg or \> 160 mm Hg, and/or
• Diastolic blood pressure \< 55 mm Hg or \> 100 mm Hg
• Abnormal resting heart rate \< 55 bpm or ≥ 110 bpm
• Sinus tachycardia that has been extensively worked up and considered benign by the recruit's personal physician may be permitted at the PI's discretion
• Sinus bradycardia between heart rates of 45 and 54 bpm may be permitted at the PI's discretion if in a clinically appropriate setting (e.g., toned athlete, taking beta blockers)
• Abnormal (i.e., non-regular) heart rhythm detected on physical exam
• Abnormal screening serum electrolytes judged by the PI to be potentially clinically significant
• Liver function abnormalities (either of the following)
• Transaminases (AST or ALT) \> 3.0 x the upper limit of normal
• Total bilirubin \> 1.25 x the upper limit of normal
• Laboratory evidence of diabetes mellitus:
• Hemoglobin A1c ≥ 6.5%, and/or
• Fasting plasma glucose ≥ 126 mg dL-1
• Positive qualitative β-hCG (i.e., pregnancy test) in women of childbearing potential
• Women currently pregnant
• Women currently breastfeeding
• History of having met any of the American Diabetes Association's definitions of diabetes mellitus (i.e., overt diabetes):
• Hemoglobin A1c ≥ 6.5%, or rapid rise in documented HbA1c values causing clinical concern for evolving insulin deficiency
• Plasma glucose ≥ 126 mg/dL after 8-h fast
• Plasma glucose of ≥ 200 mg/dL at 2 h after ingestion of a 75-g glucose load
• Random plasma glucose ≥ 200 mg/dL associated with typical hyperglycemic symptoms, diabetic ketoacidosis, or hyperglycemic-hyperosmolar state
• History of gestational diabetes mellitus within the previous 5 years
• Use of most antidiabetic medications within the 90 days prior to screening
• Exceptions: thiazolidinediones, sulfonylureas, meglitinides, DPP4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, amylin mimetics, acarbose, insulin
• Metformin is acceptable provided that recruits meet all of the inclusion criteria at screening
• Clinical concern for absolute insulin deficiency (e.g., type 1 diabetes, pancreatic disease)
• Cardiovascular diseases (N.B. uncomplicated hypertension is not exclusionary)
• Atherosclerotic cardiovascular disease
• Stable or unstable angina
• Myocardial infarction
• Ischaemic or hemorrhagic stroke
• Peripheral arterial disease (claudication)
• Use of dual antiplatelet therapy (aspirin + P2Y12 inhibitor)
• History of percutaneous coronary intervention
• Congestive heart failure (NYHA Class ≥ 2)
• Severe valvular heart disease (e.g., aortic stenosis)
• Pulmonary hypertension
• Advanced or severe liver disease, including but not limited to:
• Advanced liver fibrosis, as determined by non-invasive testing
• Cirrhosis of any etiology
• Autoimmune hepatitis or other rheumatologic disorder affecting the liver
• Biliopathy (e.g., progressive sclerosing cholangitis, primary biliary cholangitis)
• Chronic liver infection (e.g., viral hepatitis, parasitic infestation)
• Hepatocellular carcinoma
• Infiltrative disorders (e.g., sarcoidosis, hemochromatosis, Wilson disease)
• Psychiatric diseases causing functional impairment that:
• Are or have been decompensated within 1 year of screening, and/or
• Require use of anti-dopaminergic antipsychotic drugs associated with significant weight gain/metabolic dysfunction (e.g., clozapine, olanzapine)
• Venous thromboembolic disease (deep vein thrombosis or pulmonary embolism) or any required use of therapeutic anticoagulation
• Bleeding disorders, including due to anticoagulation, or significant anemia (see above)
• Active malignancy, or hormonally active benign neoplasm, except allowances for:
• Non-melanoma skin cancer
• Differentiated thyroid cancer (AJCC Stage I only)
• Clinical concern for increased risk of volume overload, including due to medications and/or heart/liver/kidney problems, as listed above
• Use of certain medications currently or within 30 days prior to screening:
• Prescribed medications used for any of the indications in the preceding list of excluded conditions, or their use within 30 d prior to screening, except allowances for:
• Use of drugs prescribed for indications other than the exclusionary diagnoses/purposes listed above (e.g., ACEi/ARB used for uncomplicated hypertension rather than for congestive heart failure, etc.)
• Note, as above, that antidiabetic drugs except metformin within 30 d of screening are excluded
• Oral or parenteral corticosteroids (at greater than prednisone 5 mg daily, or equivalent) for more than 3 days within the previous 30 days; topical and inhaled formulations are permitted
• History of certain weight-loss (bariatric) surgery, including:
• Roux-en-Y gastric bypass
• Biliopancreatic diversion
• Restrictive procedures (lap band, sleeve gastrectomy) performed within the past 6 months
• Clinical concern for alcohol overuse based on chart review and/or by recruit's report of more than 14 standard drinks per week for males or more than 7 standard drinks per week for females
• Regular tobacco use (smoking more than 1 cigarette per week) or regular nicotine vaping (daily)
• Clinical concern for use of illicit drugs other than marijuana or lawfully prescribed medications based on recruit's report, chart review, and point-of-care urine drug test at screening
• History of or ongoing febrile illness within 14 days of screening
• Any other disease or condition or laboratory value that, in the opinion of the investigator, would place the participant at an unacceptable risk and/or interfere with the analysis of study data.
• Known allergy/hypersensitivity to any component of the medicinal product formulations (including soy, cow dairy, or gluten), other biologics, venipuncture materials, plastics, adhesive or silicone, or ongoing clinically important allergy/hypersensitivity as judged by the investigator.
• Concurrent enrollment in another clinical study of any investigational drug/biologic therapy within 5 half-lives of an investigational agent or biologic.